.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Chubb
Argus Health
Covington
Express Scripts
Teva
Citi
Dow
McKinsey
Farmers Insurance

Generated: December 15, 2017

DrugPatentWatch Database Preview

EPANED Drug Profile

« Back to Dashboard

When do Epaned patents expire, and when can generic versions of Epaned launch?

Epaned is a drug marketed by Silvergate Pharms and is included in two NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one patent family member in one country.

The generic ingredient in EPANED is enalapril maleate. There are twenty-seven drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the enalapril maleate profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Silvergate PharmsEPANEDenalapril maleateSOLUTION;ORAL208686-001Sep 20, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Silvergate PharmsEPANED KITenalapril maleateFOR SOLUTION;ORAL204308-001Aug 13, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Silvergate PharmsEPANED KITenalapril maleateFOR SOLUTION;ORAL204308-001Aug 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for EPANED

Drugname Dosage Strength RLD Submissiondate
enalapril maleatePowder for Oral Solution1 mg/mLEpaned Kit6/21/2016

International Patent Family for Tradename: EPANED

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2017161339► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Dow
US Department of Justice
AstraZeneca
Cipla
Federal Trade Commission
Farmers Insurance
Argus Health
Daiichi Sankyo
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot